TELA Bio, Inc.
TELA
Positions held
Your positionsTELA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $47.40M | Enterprise value | $74.63M | Trailing P/E | — | Forward P/E | -2.33 |
| PEG | — | Price / book | -2.97 | Beta | 1.36 | Dividend yield | 0.00% |
| Revenue growth | -4.5% | Earnings growth | — | Gross margin | 68.3% | Operating margin | -48.1% |
| Profit margin | -51.5% | ROE | — | ROA | -33.4% | Debt / equity | — |
| Current ratio | 2.99 | Free cash flow | -$17.71M | Analyst recommendation | strong_buy | Mean target | $2.08 |
| 52w high | $1.56 | 52w low | $0.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $19.3M | $19.1M | $20.9M | $20.7M | $20.2M | — |
| Op margin | -48.1% | -55.2% | -31.9% | -36.5% | -45.0% | — |
| Net income | -$11.3M | -$12.3M | -$9.0M | -$8.6M | -$9.9M | — |
| Gross margin | 72.3% | 65.7% | 65.9% | 67.5% | 69.8% | — |
| Gross profit | $13.9M | $12.5M | $13.8M | $14.0M | $14.1M | — |
| Operating income | -$9.3M | -$10.5M | -$6.6M | -$7.6M | -$9.1M | — |
- Revenue +1% vs prior quarter ($19M vs $19M).
- Gross margin 72.3% (was 65.7% prior quarter).
- Operating margin expanded to -48.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $80.3M | $69.3M | $58.5M | $41.4M | — |
| Op margin | -42.0% | -60.2% | -75.4% | -94.2% | — |
| Net income | -$38.8M | -$37.8M | -$46.7M | -$44.3M | — |
| Gross margin | 67.7% | 67.1% | 68.6% | 65.3% | — |
| Gross profit | $54.3M | $46.5M | $40.1M | $27.0M | — |
| Operating income | -$33.8M | -$41.7M | -$44.1M | -$39.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
2026-08-31 · TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative
2026-08-19 · TELA Bio (TELA) Q2 2026 Earnings Call Transcript
2026-08-11 · TELA Bio Inc (TELA) (Q2 2026) Earnings Call Highlights: Navigating PRS Headwinds and Strategic ...
2026-08-11 · TELA Bio, Inc. Q2 2026 Earnings Call Summary
2026-08-10 · TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
2026-08-10 · TELA Bio Reports Second Quarter 2026 Financial Results
2026-08-07 · Earnings To Watch: TELA Bio Inc (TELA) Q2 2026 -- GF Value Sees 97% Upside
2026-08-05 · TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-04 · TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director
2026-07-29 · TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
2026-07-20 · TELA Bio to Announce Second Quarter 2026 Financial Results
Price (daily)
Full chart · RSI · MACD · patterns